Lantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F18), PYLARIFY AI and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

NORTH BILLERICA, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, announced the following presentations at the upcoming 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Meeting, which will be held June 11-14, 2022 in Vancouver, BC, Canada.

Presentation details are as follows:

PYLARIFY (Piflufolastat F18), PSMA-targeted PET imaging agent for prostate cancer
Oral Presentation:
Date & Time: June 14, 2022, 3:00 – 4:30 PM PT
Session Title: Urologic Malignancies
Title: The Impact of Concomitant Use of Androgen Deprivation Therapies (ADT) on the Efficacy of Piflufolastat F 18-PET/CT in Patients with Prostate Cancer: a Sub-group Analysis of OSPREY Cohort B
Presenter: Lawrence Saperstein, MD, Associate Professor of Clinical Radiology and Biomedical Imaging; Chief, Nuclear Medicine, Yale School of Medicine
Publication (Program ID): 2625

PYLARIFY AI, FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans
Oral Presentation:
Date & Time: June 12, 2022, 3:00 – 4:30 PM PT
Session Title: Oncology Basic/Translational Integrated Session
Title: Prospectively planned and Independent Validation of aPROMISE in a Phase III CONDOR Study for Rapid Lesion Detection and Standardized Quantitative Evaluation for ¹⁸F-DCFPyL (PSMA) Imaging in Prostate Cancer*
Presenter: Jeremie Calais, MD, MSc, Assistant Professor, Department of Molecular and Medical Pharmacology, Director, UCLA Theranostics Program, Ahmanson Translational Theranostics Division, University of California, Los Angeles
Publication (Program ID): 2496
*nominated for the Henry N. Wagner, Jr., MD “Image of the Year”

Poster Presentation:
Title: Quantitative Assessment of PSMA PET Response to Androgen Deprivation in Veterans with Treatment Naïve Castration Sensitive Prostate Cancer
Presenter: Nicholas G. Nickols, MD, PhD, Associate Professor in Radiation Oncology at UCLA
Publication (Program ID): 3070

Tc99m-NM-01, novel imaging agent currently under development for the assessment of PD-L1 expression in non-small cell lung cancer
Oral Presentation:
Date & Time: June 12, 2022, 12:30 – 2:00 PM PT
Session Title: Thoracic Malignancies: Breast and Lung
Title: SPECT/CT using ^99mTc-labeled anti-programmed death-ligand 1 (PD-L1) single-domain antibody (NM-01) to predict response to immune checkpoint inhibition in non-small cell lung cancer: preliminary results from the PD-L1 Expression in Cancer (PECan) study